<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04364789</url>
  </required_header>
  <id_info>
    <org_study_id>TT00920US01</org_study_id>
    <nct_id>NCT04364789</nct_id>
  </id_info>
  <brief_title>Phase I, First-In-Human Study of TT-00920 in Healthy Subjects</brief_title>
  <official_title>A Phase I, First-In-Human, Randomized, Double-blind, Placebo-controlled, Single-Ascending-Dose Study of TT-00920 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TransThera Sciences (Nanjing), Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TransThera Sciences (Nanjing), Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human, randomized, double-blind, placebo-controlled study. The primary&#xD;
      objectives of the study were to investigate the safety and tolerability and determine the PK&#xD;
      profiles of single ascending doses (SAD) of TT-00920 administered to healthy subjects. The&#xD;
      secondary objectives of the study were to assess the effect of food on the PK of TT-00920&#xD;
      following an oral dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be 4 single-ascending-dose cohorts and 1 cohort for food effect assessment to&#xD;
      assess the safety, tolerability, and PK profile. A pilot dose of 20 mg will be evaluated in 2&#xD;
      subjects (all receiving TT-00920) for safety, tolerability, and PK profile before the&#xD;
      initiation of dose escalation.&#xD;
&#xD;
      In single-ascending-dose cohorts, 8 subjects per cohort will be enrolled and randomized to&#xD;
      assess the safety, tolerability, and PK profile. In food effect cohort, there will be 8&#xD;
      subjects (all receiving TT-00920). Subjects in food effect cohort will receive 2 single dose&#xD;
      periods (Fasted/ Fed) in an open-label, crossover design.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 5, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 18, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double (Paticipant, Investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Numbers of Treatment Emergent Adverse Events(TEAE)</measure>
    <time_frame>10 days</time_frame>
    <description>Safety and tolerability of TT-00920</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Abnormal Laboratory Values</measure>
    <time_frame>10 days</time_frame>
    <description>Safety and tolerability of TT-00920</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma drug concentration versus time curve</measure>
    <time_frame>10 days</time_frame>
    <description>PK parameters of TT-00920</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>10 days</time_frame>
    <description>PK parameters of TT-00920</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of First Occurrence of Cmax （tmax) Time of first Occurance of Cmax（tmax)</measure>
    <time_frame>10 days</time_frame>
    <description>PK parameters of TT-00920</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>10 days</time_frame>
    <description>PK parameters of TT-00920</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination rate (λz)</measure>
    <time_frame>10 days</time_frame>
    <description>PK parameters of TT-00920</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution (Vz/F)</measure>
    <time_frame>10 days</time_frame>
    <description>PK parameters of TT-00920</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (CL/F)</measure>
    <time_frame>10 days</time_frame>
    <description>PK parameters of TT-00920</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma drug concentration versus time curve</measure>
    <time_frame>10 days</time_frame>
    <description>the effect of food on the PK of TT-00920 following an oral dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>10 days</time_frame>
    <description>the effect of food on the PK of TT-00920 following an oral dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of first Occurance of Cmax（tmax)</measure>
    <time_frame>10 days</time_frame>
    <description>the effect of food on the PK of TT-00920 following an oral dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>10 days</time_frame>
    <description>the effect of food on the PK of TT-00920 following an oral dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination rate (λz)</measure>
    <time_frame>10 days</time_frame>
    <description>the effect of food on the PK of TT-00920 following an oral dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vz/F)</measure>
    <time_frame>10 days</time_frame>
    <description>the effect of food on the PK of TT-00920 following an oral dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL/F)</measure>
    <time_frame>10 days</time_frame>
    <description>the effect of food on the PK of TT-00920 following an oral dose</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Metabolite characterization in plasma and estimation of observed drug-related material in plasma to determine the presence of any metabolite &gt;10%</measure>
    <time_frame>10 days</time_frame>
    <description>Exploratory outcome measures</description>
  </other_outcome>
  <other_outcome>
    <measure>Cyclic guanosine monophosphate (cGMP) levels in plasma and urine</measure>
    <time_frame>10days</time_frame>
    <description>Exploratory outcome measures</description>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Pilot dose Cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A pilot dose of 20 mg will be evaluated in 2 subjects (all receiving TT-00920) for safety, tolerability, and PK profile before the initiation of dose escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Dose 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Dose 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Dose 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Dose 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Food Effect Cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TT-00920</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Food Effect Cohort</arm_group_label>
    <arm_group_label>Pilot dose Cohort</arm_group_label>
    <arm_group_label>SAD Dose 1</arm_group_label>
    <arm_group_label>SAD Dose 2</arm_group_label>
    <arm_group_label>SAD Dose 3</arm_group_label>
    <arm_group_label>SAD Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent must be obtained before any assessment is performed.&#xD;
&#xD;
          -  Age ≥ 18 years and ≤ 55 years, male or female of non-childbearing potential (confirmed&#xD;
             with follicle stimulating hormone [FSH] test. A bilateral tubal ligation is acceptable&#xD;
             as long as there is no fertility potential).&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 30 kg/m2, inclusive, and weighs at least 50 kg.&#xD;
&#xD;
          -  No clinically significant findings in medical examination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any history of clinically serious disease.&#xD;
&#xD;
          -  Hypersensitivity or allergy to any of the study drugs or drugs of similar chemical&#xD;
             classes.&#xD;
&#xD;
          -  Impaired cardiac function including clinically significant arrhythmias or clinically&#xD;
             significant abnormality in clinical test&#xD;
&#xD;
          -  Subject with a history of severe visual diseases; or visual changes including flushing&#xD;
             lights, blurry vision, color changes, or other visual changes; or abnormal finding&#xD;
             with visual tests [color discrimination (Ishihara test) and visual acuity (Snellen&#xD;
             chart).&#xD;
&#xD;
          -  Subject is unable to complete this study for other reasons or the Investigator&#xD;
             believes that he or she should be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gevorkyan Hakop, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Early Phase Clinical Unit Glendale Adventist Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Early Phase Clinical Unit Glendale Adventist Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 21, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

